LONDON (Alliance News) - Vectura Group PLC and Skyepharma PLC on Monday said that the UK's Competition & Markets Authority confirmed their proposed merger does not qualify for investigation under investigation under the Enterprise Act 2002.
Vectura and Skyepharma, which are both focused on treatments for asthma and other respiratory illnesses, agreed to an all-share merger in March.
Shares in Vectura closed up 0.9% at 169.4 pence. Shares in Skyepharma closed up 1.0% at 467.90p.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2016 Alliance News Limited. All Rights Reserved.
